--- title: "Key facts: STRIDE+TACE improves PFS in HCC; AZ cuts US drug prices 80%" type: "News" locale: "zh-CN" url: "https://longbridge.com/zh-CN/news/281590099.md" description: "AstraZeneca: EMERALD-3 trial showed STRIDE (tremelimumab + durvalumab) plus TACE ± lenvatinib improved progression-free survival versus TACE alone in hepatocellular carcinoma.1AstraZeneca will cut U.S. prescription prices, offering discounts up to 80% via the TrumpRx.gov platform for eligible U.S. medications; announcement made in October.2" datetime: "2026-04-03T01:03:44.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/281590099.md) - [en](https://longbridge.com/en/news/281590099.md) - [zh-HK](https://longbridge.com/zh-HK/news/281590099.md) --- > 支持的语言: [English](https://longbridge.com/en/news/281590099.md) | [繁體中文](https://longbridge.com/zh-HK/news/281590099.md) # Key facts: STRIDE+TACE improves PFS in HCC; AZ cuts US drug prices 80% - AstraZeneca: EMERALD-3 trial showed STRIDE (tremelimumab + durvalumab) plus TACE ± lenvatinib improved progression-free survival versus TACE alone in hepatocellular carcinoma.1 - AstraZeneca will cut U.S. prescription prices, offering discounts up to 80% via the TrumpRx.gov platform for eligible U.S. medications; announcement made in October.2 ### 相关股票 - [AstraZeneca (AZN.US)](https://longbridge.com/zh-CN/quote/AZN.US.md) ## 相关资讯与研究 - [AstraZeneca says Efzimfotase alfa PH3 program show positive results](https://longbridge.com/zh-CN/news/281138062.md) - [If You Invested $1000 In AstraZeneca Stock 10 Years Ago, You Would Have This Much Today](https://longbridge.com/zh-CN/news/281048213.md) - [AstraZeneca's Efzimfotase Alfa Shows Improved Bone Health in Late-stage Clinical Trials](https://longbridge.com/zh-CN/news/281136189.md) - [AstraZeneca's liver cancer therapy combo slows disease progression in late-stage trial](https://longbridge.com/zh-CN/news/281509606.md) - [AstraZeneca hails positive results in tozorakimab lung disease trials](https://longbridge.com/zh-CN/news/280752841.md)